Researchers describe alternative psoriasis targetBritish researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want … more ➔
Neurim tables Phase III data of insomnia drugGerman-Israeli Neurim Pharmaceuticals announced top line efficacy results of its insomnia drug PedPRM in children with autism spectrum disorders (ASD). more ➔
Erytech Pharma set to raise US$100m in IPO and private placementFrench cancer drug encapsulation specialist Erytech Pharma SA wants to raise US$100m (€85m) in an IPO at NASDAQ and a subsequent private placement outside Northern America to finance pivotal trials … more ➔
uniQure’s AMT-130 receives FDA Orphan Drug Designation in Huntington’s disease As first gene therapy ever, AMT-130 has been granted FDA Orphan Drug status in Huntington’s Disease. more ➔
Promethera Biosciences partners with Shibuya Corp Promethera Biosciences and Shibuya collaborate to establish a breakthrough cell therapy manufacturing platform. more ➔
Immatics raises $58m Cancer immunotherapy specialist Immatics Biotechnologies GmbH (Tuebingen, Germany) raised US$58m in a Series E financing round led by German investors dievini Hopp BioTech Holding and AT Impf as well … more ➔
NuCana raises US$114m in IPO of ADSsScotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair. more ➔
Researchers unravel patterns of cancer heterogeneityUp to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported … more ➔
Ablynx takes Phase III hurdle in acquired TTPBelgian nanobody developer Ablynx NV’s nanobody caplacizumab has met relevant endpoints in the pivotal Hercules Phase III study in patients with thrombotic thrombocytopenic purpura (aTTP), paving … more ➔
Dipstick test detects ZikaA newly-developed, fast, and cost-effective dipstick test sensitively and specifically identified Zika virus and all four dengue virus subtypes without any detectable cross-reactivity. more ➔
